Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 13/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979217 | 1.00 | PIM1 (0.40) | PIM1PIM2RETCSNK2BIRAK4 | |
| SCHEMBL3483134 | 1.00 | PIM1 (0.40) | PIM1PIM2RETCSNK2BIRAK4 | |
| SCHEMBL862082 | 0.84 | MEN1 (0.36) | PIM1PIM2RETCSNK2BKDM4E | |
| SCHEMBL862081 | 0.84 | MEN1 (0.36) | PIM1PIM2RETCSNK2BKDM4E | |
| SCHEMBL860772 | 0.81 | MEN1 (0.38) | CSNK2BKDM4EALDH1A1HPGDPKM | |
| SCHEMBL12979184 | 0.81 | MEN1 (0.38) | CSNK2BKDM4EALDH1A1HPGDPKM | |
| SCHEMBL860323 | 0.79 | PIM1 (0.45) | PIM1PIM2RETIRAK4 | |
| SCHEMBL12979564 | 0.78 | GSK3B (0.42) | PIM1RETCSNK2BKDM4EALDH1A1 | |
| SCHEMBL860452 | 0.78 | GSK3B (0.42) | PIM1RETCSNK2BKDM4EALDH1A1 | |
| SCHEMBL860453 | 0.78 | GSK3B (0.42) | PIM1RETCSNK2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885PIM2 2/4885RET 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.